

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

A2780cis

RRID:CVCL_1942

Type: Cell Line

Proper Citation

RRID:CVCL_1942

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1942

Proper Citation: RRID:CVCL_1942

Description: Cell line A2780cis is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian endometrioid adenocarcinoma

Defining Citation: [PMID:11416159](#), [PMID:18273836](#), [PMID:20215515](#), [PMID:22585861](#), [PMID:25230021](#), [PMID:28273451](#), [PMID:30971826](#), [PMID:34071702](#)

Comments: Population: African American., Part of: OCCP ovarian cancer cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A2780cis

Synonyms: A2780Cis, A2780CIS, A2780_CIS, A2780 CIS

Cross References: CLO:CLO_0001573, CLDB:cl195, AddexBio:C0017003/4911, BioGRID_ORCS_Cell_line:827, cancercellines:CVCL_1942, CancerTools:152708, Cell_Model_Passport:SIDM01212, ChEMBL-Cells:ChEMBL4295428, ECACC:93112517, GEO:GSM827456, GEO:GSM1291128, GEO:GSM2474972, LINCS_LDP:LCL-1696, Progenetix:CVCL_1942, PubChem_Cell_line:CVCL_1942, Wikidata:Q54606614, Ximbio:152708

ID: CVCL_1942

Hierarchy: cvcl_0134

Record Creation Time: 20220427T215106+0000

Record Last Update: 20260913T011854+0000

Ratings and Alerts

No rating or validation information has been found for A2780cis.

No alerts have been found for A2780cis.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Santer FR, et al. (2026) Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. Scientific reports, 16(1).

Miglietta S, et al. (2025) Mitochondrial chaperonin DNAJC15 promotes vulnerability to ferroptosis of chemoresistant ovarian cancer cells. Open biology, 15(1), 240151.

Koltun B, et al. (2025) Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance. Molecular cancer therapeutics, 24(11), 1815.

Han J, et al. (2025) Pluripotent stem cell-derived chimeric antigen receptor-natural killer cells targeting epidermal growth factor receptor 2 for cancer immunotherapy. BMB reports, 58(11), 475.

Wang W, et al. (2025) Engineered Extracellular Vesicles Enriched with miR-214 Enhance the Efficacy of Chemotherapy for Ovarian Cancer. bioRxiv : the preprint server for biology.

Gagliardi S, et al. (2024) Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells. Cell communication and signaling : CCS, 22(1), 165.

Carmi YK, et al. (2024) Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells. Translational oncology, 44, 101939.

Gobbo A, et al. (2024) Anticancer potential of NSAID-derived tris(pyrazolyl)methane ligands in iron(II) sandwich complexes. Dalton transactions (Cambridge, England : 2003), 53(32), 13503.

Kunisky AK, et al. (2021) Shift in MSL1 alternative polyadenylation in response to DNA damage protects cancer cells from chemotherapeutic agent-induced apoptosis. Cell

reports, 37(2), 109815.

Xu X, et al. (2021) Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. *British journal of cancer*, 125(2), 265.

Malgundkar SH, et al. (2020) FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β -catenin activity in ovarian cancer. *BMC cancer*, 20(1), 374.

Naskou J, et al. (2020) EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. *Molecular cancer research : MCR*, 18(2), 278.

Ma Q, et al. (2020) Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells. *Cell reports*, 31(3), 107532.

Wang Z, et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer cell*, 33(4), 706.

He S, et al. (2017) The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF- κ B signaling pathway. *Journal of experimental & clinical cancer research : CR*, 36(1), 137.